甘丙肽及其受体亚型在人乳腺癌标本中的表达

doi:10.3969/j.issn.1006-7795.2016.02.020

首都医科大学学报 ›› 2016, Vol. 37 ›› Issue (2): 214-218.doi: 10.3969/j.issn.1006-7795.2016.02.020

甘丙肽及其受体亚型在人乳腺癌标本中的表达

张帅¹, 邓佳卉², 徐志卿³, 戚晓东¹

1. 安徽医科大学北京军区总医院临床学院乳腺科, 北京 100700;
2. 首都医科大学三博脑科医院功能神经外科, 北京 100093;
3. 首都医科大学基础医学院神经生物学系, 北京 100069

收稿日期:2016-03-10 出版日期:2016-04-21 发布日期:2016-04-14
通讯作者: 戚晓东 E-mail:qixiaodongbj@sina.com
基金资助:
国家中医管理局2012全国名老中医药专家传承工作室建设项目([2012]149),国家临床重点专科(中医专业)建设项目(2100299),国家中医药管理局"十二五"中医药重点学科([2012]174), 中医药管理局科技发展基金项目(JJ2007-017)

Expression of galanin and its receptor subtypes in human breast cancer

Zhang Shuai¹, Deng Jiahui², Xu Zhiqing³, Qi Xiaodong¹

1. Department of Breast, the Military General Hospital of Beijing, Clinical School of Anhui Medical University, Beijing 100700, China;
2. Department of Functional Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China;
3. Department of Neurobiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China

Received:2016-03-10 Online:2016-04-21 Published:2016-04-14
Supported by:
This study was supported by National Natural Science Construction Program for Inheritance Office of National Famous Old Traditional Chinese Medicine Experts in 2012 ([2012]149), National Clinical Key Subject (Major of Chinese Medicine) Construction Project (2100299), Key Discipline of State Administration of Traditional Chinese Medicine in the 'Twelfth Five-year' Plan ([2012]174), State Administration of Traditional Chinese Medicine of People's Republic of China(JJ2007-017).

摘要/Abstract

摘要： 目的探索甘丙肽(galanin,GAL)及其受体亚型(galanin receptor1、2、3, GALR1、2、3)在乳腺癌及癌周组织中的表达情况,分析其与不同临床治疗方法的关系。方法 qRT-PCR法检测乳腺癌及癌周组织的GAL及其3种受体亚型mRNA的表达情况。Western blotting分析GAL在乳腺癌及癌周组织中的表达情况。t检验分析不同术前处理组之间癌组织的GAL及其受体亚型表达的变化,而配对t检验用于分析同一术前处理组内癌组织和癌周组织之间GAL及其受体亚型表达的变化。结果在术前无治疗组中,癌组织GAL mRNA及GAL蛋白比癌旁组织高(P<0.05,P<0.01),而GALR1、GALR2、GALR3 mRNA比癌旁组织低(P<0.05,P<0.05,P<0.01)。经过新辅助化学治疗(neoadjuvant chemotherapy, NAC)与高强度聚焦超声射频消融术(high intensity focused ultrasound, HIFU)治疗后,癌组织与癌旁组织相比,GAL及其受体mRNA和蛋白差异无统计学意义,但是与术前无治疗组癌组织相比,GAL mRNA及GAL蛋白明显降低(P<0.05)。此外,经过NAC治疗后癌组织中GALR3 mRNA要明显高于术前无治疗组的癌组织(P<0.01)。结论 GAL及其受体亚型在乳腺癌中存在异常表达,并与临床治疗方法有关,可能为乳腺癌的诊断、治疗及预后提供了新的生物学标志。

关键词: 乳腺癌, 甘丙肽, 甘丙肽受体亚型

Abstract: Objective To determine the expression of galanin(GAL) and galanin receptor 1、2、3 (GALR1、2、3) in breast cancer and the paired peritumoral tissues; To analyze the relationship between the different clinical therapies and the expression of galanin and its receptor subtypes. Methods qRT-PCR was performed to detect the mRNA level of galanin and its three receptor subtypes in breast cancer and the paired peritumoral tissues. Western blotting was carried out to detect the GAL protein level in breast cancer and the paired peritumoral tissues. t-test was used to analyze the expression of galanin and its three receptor subtypes in cancer tissues of different groups; while paired t-test was performed to analyze the expression of galanin and its three receptor subtypes in breast cancer and the paired peritumoral tissues of the same group. Results The GAL mRNA and protein levels of cancer tissues were higher than the paired peritumoral tissues in the group of no preoperative treatment (P<0.05, P<0.01), whereas the mRNA levels of GALR1, GALR2 and GALR3 were lower than the paired peritumoral tissue (P<0.05, P<0.05, P<0.01). In the NAC and HIFU groups, there were no significant differences in GAL protein, GAL and its receptors mRNA levels between the cancer and the paired peritumoral tissues (P<0.05, P<0.05, P<0.01). However, the GAL protein and GAL mRNA levels were lower than the group of no preoperative treatment (P<0.05). In addition, the GALR3 mRNA level was higher than the group of no preoperative treatment in the NAC group (P<0.01). Conclusion The abnormal expression of galanin and its receptor subtypes in breast cancer was relevant to different clinical therapies, which might be used as a potential biomarker for breast cancer diagnosis, therapy and prognosis.

Key words: breast cancer, galanin, galanin receptor subtypes

中图分类号:

R739.9

张帅, 邓佳卉, 徐志卿, 戚晓东. 甘丙肽及其受体亚型在人乳腺癌标本中的表达[J]. 首都医科大学学报, 2016, 37(2): 214-218.

Zhang Shuai, Deng Jiahui, Xu Zhiqing, Qi Xiaodong. Expression of galanin and its receptor subtypes in human breast cancer[J]. Journal of Capital Medical University, 2016, 37(2): 214-218.

参考文献

[1] DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013[J]. CA Cancer J Clin, 2014, 64(1):52-62.
[2] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[3] Ahmed S, Sami A, Xiang J. HER2-directed therapy:current treatment options for HER2-positive breast cancer[J]. Breast Cancer, 2015, 22(2):101-116.
[4] Lang R, Gundlach A L, Kofler B. The galanin peptide family:receptor pharmacology, pleiotropic biological actions, and implications in health and disease[J]. Pharmacol Ther, 2007, 115(2):177-207.
[5] Rauch I, Kofler B. The galanin system in cancer[J]. EXS, 2010, 102:223-241.
[6] Kim K Y, Kee M K, Chong S A, et al. Galanin is up-regulated in colon adenocarcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2007, 16(11):2373-2378.
[7] Ormandy C J, Lee C S, Ormandy H F, et al. Amplification, expression, and steroid regulation of the preprogalanin gene in human breast cancer[J]. Cancer Res, 1998, 58(7):1353-1357.
[8] Chung W, Kwabi-Addo B, Ittmann M, et al. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling[J]. PLoS One, 2008, 3(4):e2079.
[9] Sugimoto T, Seki N, Shimizu S, et al. The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma[J]. Genes Chromosomes Cancer, 2009, 48(2):132-142.
[10] Kanazawa T, Iwashita T, Kommareddi P, et al. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells:activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors[J]. Oncogene, 2007, 26(39):5762-5771.
[11] Kanazawa T, Misawa K, Misawa Y, et al. G-protein-coupled receptors:next generation therapeutic targets in head and neck cancer?[J]. Toxins (Basel), 2015, 7(8):2959-2984.
[12] Norum J H, Andersen K, Sorlie T. Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy[J]. Br J Surg, 2014, 101(8):925-938.
[13] Stevenson L, Allen W L, Turkington R, et al. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer[J]. Clin Cancer Res, 2012, 18(19):5412-5426.
[14] Kim J C, Lee H C, Cho D H, et al. Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers[J]. J Cancer Res Clin Oncol, 2011, 137(10):1571-1580.
[15] Huang X, Yuan F, Liang M, et al. M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer[J]. PLoS One, 2012, 7(7):e41632.

甘丙肽及其受体亚型在人乳腺癌标本中的表达

Expression of galanin and its receptor subtypes in human breast cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[2]	魏常胜, 骆成玉, 张树琦. 环乳晕切口联合乳腔镜腋窝淋巴结清扫在早期乳腺癌保乳手术中的应用[J]. 首都医科大学学报, 2021, 42(6): 1014-1020.
[3]	中华预防医学会妇女保健分会; 中国人体健康科技促进会妇科内分泌与生育力促进专委会. 乳腺癌患者选择性雌激素受体调节剂治疗相关子宫内膜安全管理的中国专家共识(2021版)[J]. 首都医科大学学报, 2021, 42(4): 672-677.
[4]	阮祥燕, 杨瑜, 卢丹, 杜娟, 程姣姣, 谷牧青, 李扬璐, 金凤羽, 段微, 代荫梅, 鞠蕊, 许新, MatthiasKorell, AlfredO.Mueck. 中国首例乳腺癌患者冻存卵巢组织移植成功报道及文献复习[J]. 首都医科大学学报, 2021, 42(2): 177-182.
[5]	杨阳, 康骅, 赵菁, 凌煜玮, 赵烨, 王亚军, 戎冬冬. 术前乳腺MRI对乳腺癌保乳手术切缘评估的回顾性分析[J]. 首都医科大学学报, 2020, 41(6): 943-953.
[6]	王爱婷, 鄢丹, 齐宪荣. 包载多西他赛的聚合物胶束抑制小鼠乳腺癌转移作用研究[J]. 首都医科大学学报, 2020, 41(2): 225-230.
[7]	王维, 张紫寒, 翟妍, 桑翠琴, 王淑珍. 子宫体、乳腺双原发癌的临床病理特征[J]. 首都医科大学学报, 2019, 40(6): 857-862.
[8]	张蕴显, 王雅梅, 周萍. 乳腺癌中基于开放染色质的环状RNA互作网络构建及功能分析[J]. 首都医科大学学报, 2019, 40(6): 901-910.
[9]	白向东, 郝雅婷, 张欣雪, 贺强. 脾多肽注射液联合术后化疗对三阴性乳腺癌患者临床疗效的研究[J]. 首都医科大学学报, 2019, 40(6): 911-915.
[10]	张凌燕, 阮祥燕, 蔡桂举, 谷牧青, Alfred O. Mueck. 他莫昔芬治疗转染孕激素受体膜组分1乳腺癌裸鼠模型对乳腺肿瘤组织Ki-67表达的影响[J]. 首都医科大学学报, 2019, 40(4): 533-538.
[11]	王月姣, 阮祥燕, 谷牧青, 蔡桂举, 李雪, 张凌燕, Alfred O. Mueck. 他莫昔芬治疗乳腺癌异种移植瘤裸鼠子宫病理改变[J]. 首都医科大学学报, 2019, 40(4): 539-543.
[12]	白向东, 郝雅婷, 张欣雪, 贺强. 雌激素受体阳性和阴性乳腺癌术后辅助化学药物治疗中加用脾多肽的临床免疫疗效观察[J]. 首都医科大学学报, 2019, 40(3): 443-448.
[13]	陈妮娜, 范怡畅, 尚昆, 杨婧, 曹邦伟. 血清血脂及载脂蛋白浓度与乳腺癌分子分型及Ki-67表达水平的相关性研究[J]. 首都医科大学学报, 2019, 40(2): 191-194.
[14]	李雪, 阮祥燕, 谷牧青, 蔡桂举, 赵越, Alfred O. Meuck. 孕激素受体膜组分1促进雌孕激素诱导的乳腺癌细胞增生的研究——雌二醇与周期序贯及连续联合比较[J]. 首都医科大学学报, 2019, 40(2): 237-243.
[15]	徐泉, 刘玉洁, 潘钰, 郑秀瑗, 刘静民, 孙小花, 邹丽丽, 马丽娜, 严红松. 生物电阻抗测试频率对乳腺癌相关淋巴水肿定量评估的影响[J]. 首都医科大学学报, 2018, 39(5): 747-751.